Description
Clinical Description
Ejal 40 is a bio-revitalising injectable medical device developed by Medixa Srl for improving skin quality, hydration, and dermal support in patients showing signs of intrinsic and extrinsic skin ageing. Classified as a skin booster and biorevitalisation treatment, Ejal 40 contains high-molecular-weight hyaluronic acid at a concentration of 40 mg per 2 ml syringe, formulated to support extracellular matrix integrity and promote a more hydrated, elastic, and refreshed appearance.
Unlike volumising dermal fillers, Ejal 40 is designed primarily to improve skin quality rather than create structural volume. The product is frequently used in protocols intended to address skin laxity, dehydration, and early age-related dermal changes affecting the face, neck, décolletage, and hands.
Through the hydrophilic properties of hyaluronic acid, Ejal 40 supports water retention within the dermis and contributes to improved tissue hydration and skin texture.
What Ejal 40 Is Similar To
Ejal 40 belongs to the same category of injectable skin boosters and biorevitalisation products as Profhilo®, Sunekos®, and other hyaluronic acid-based regenerative aesthetic treatments.
Compared with Profhilo®, which combines high- and low-molecular-weight hyaluronic acid using a thermal stabilisation process, Ejal 40 uses high-molecular-weight hyaluronic acid designed to support skin hydration and dermal quality through bio-revitalisation protocols.
Compared with Sunekos®, which combines hyaluronic acid with amino acids to support extracellular matrix activity, Ejal 40 focuses primarily on high-concentration hyaluronic acid as its principal active ingredient.
All of these products are intended to improve skin quality rather than provide significant volumisation. Treatment schedules, clinical outcomes, and longevity may differ depending on patient characteristics and practitioner protocols.
This comparison is provided for clinical orientation only and does not imply interchangeability.
Treatment Areas / Indications
According to manufacturer documentation, Ejal 40 may be used in areas showing signs of skin ageing and reduced dermal quality, including:
- Face
- Neck
- Décolletage
- Hands
Clinical objectives include:
- Improvement of skin hydration
- Enhancement of skin elasticity
- Support of dermal revitalisation
- Management of age-related skin changes
Usage / Administration (IFU-Only)
Injection depth: Intradermal injection.
Frequency / number of sessions: Publicly available manufacturer documentation describes treatment cycles; however, exact frequency parameters are not consistently specified in accessible IFU documentation. Therefore: not provided by manufacturer.
Professional-use disclaimer: Ejal 40 should be administered exclusively by qualified medical professionals trained in aesthetic injection procedures and under appropriate aseptic conditions.
Some practitioners utilise the well-known 4-point BioRevitalization Technique (4PBT®) with Ejal 40; however, specific practitioner protocols may vary and should not be considered a substitute for the manufacturer’s official IFU.
Ingredient List
Active Ingredients
- Hyaluronic Acid (High Molecular Weight): 40 mg / 2 ml
Excipients
- Physiological buffered solution
- Sodium chloride
- Water for injection
Lidocaine: No.
Presentation & Longevity
Packaging
- 1 × 2 ml sterile prefilled syringe
- Single-use medical device
Treatment Duration / Longevity
Longevity is not explicitly guaranteed by the manufacturer and may vary according to patient characteristics, treatment area, lifestyle factors, and practitioner protocol. Publicly available clinical and distributor information suggests treatment programmes commonly involve multiple sessions, but exact duration is not provided by manufacturer.
Safety Notes / Contraindications
According to manufacturer guidance and standard injectable medical-device precautions, Ejal 40 should not be used in:
- Patients with known hypersensitivity to hyaluronic acid or any formulation component.
- Patients with active skin infections or inflammatory conditions at the intended treatment site.
- Patients with severe autoimmune disorders where treatment is considered unsuitable by the treating physician.
- Pregnant or breastfeeding patients unless specifically assessed by an appropriately qualified healthcare professional.
Additional precautions include:
- Avoid intravascular injection.
- Use only under aseptic conditions.
- Do not use damaged or previously opened syringes.
Regulatory Status
- CE-marked medical device.
- Intended for professional medical use only.
- Manufactured by Medixa Srl, Italy.
UKCA status: Verify via current IFU, importer documentation, or authorised UK distributor.
FAQ
1. What is Ejal 40 used for?
Ejal 40 is a hyaluronic acid-based bio-revitalisation treatment designed to improve skin hydration, elasticity, and overall dermal quality. It is commonly used in aesthetic medicine for patients presenting with skin ageing, dehydration, and reduced firmness.
2. Is Ejal 40 a dermal filler?
Ejal 40 differs from traditional dermal fillers because its primary objective is skin revitalisation rather than volumisation. While it contains hyaluronic acid, the treatment focuses on improving skin quality and hydration rather than restoring facial volume or contour.
3. What areas can be treated with Ejal 40?
Manufacturer information identifies the face, neck, décolletage, and hands as principal treatment areas. These regions commonly exhibit age-related changes such as dehydration, reduced elasticity, and diminished skin quality.
4. Does Ejal 40 contain lidocaine?
No. Public manufacturer specifications indicate that Ejal 40 contains high-molecular-weight hyaluronic acid in a physiological buffer but does not contain lidocaine.
5. How does Ejal 40 compare with other skin boosters?
Ejal 40 belongs to the same broad category as Profhilo® and Sunekos®. While all aim to improve skin quality, they differ in formulation technology and ingredient composition. Ejal 40 relies primarily on high-concentration hyaluronic acid for bio-revitalisation and hydration support.
